{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:29:55Z","timestamp":1792877395287,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,28]]},"DOI":"10.7759\/cureus.59210","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T14:24:14Z","timestamp":1714314254000},"source":"Crossref","is-referenced-by-count":18,"title":["Fosmanogepix: The Novel Anti-Fungal Agent\u2019s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials"],"prefix":"10.7759","author":[{"given":"Ali","family":"Almajid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim M","family":"Al-awami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Albarbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Alsuwayj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan","family":"Aljawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Alnimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouq","family":"Alajlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Alshelali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamama","family":"Aljishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126713","article-title":"Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp","volume":"29","author":"Trzoss M","year":"2019","unstructured":"Trzoss M, Covel JA, Kapoor M, Moloney MK, Soltow QA, Webb PJ, Shaw KJ. Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp. Bioorg Med Chem Lett. 2019, 29:126713. 10.1016\/j.bmcl.2019.126713","journal-title":"Bioorg Med Chem Lett"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki M","year":"2011","unstructured":"Miyazaki M, Horii T, Hata K, et al.. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011, 55:4652-8. 10.1128\/AAC.00291-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe NA","year":"2012","unstructured":"Watanabe NA, Miyazaki M, Horii T, Sagane K, Tsukahara K, Hata K. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother. 2012, 56:960-71. 10.1128\/AAC.00731-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1021\/id5000212","article-title":"Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis","volume":"1","author":"Mann PA","year":"2015","unstructured":"Mann PA, McLellan CA, Koseoglu S, et al.. Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis. ACS Infect Dis. 2015, 1:59-72. 10.1021\/id5000212","journal-title":"ACS Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara K","year":"2003","unstructured":"Tsukahara K, Hata K, Nakamoto K, et al.. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol Microbiol. 2003, 48:1029-42. 10.1046\/j.1365-2958.2003.03481.x","journal-title":"Mol Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2012.738312","article-title":"Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults","volume":"51","author":"Denning DW","year":"2013","unstructured":"Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013, 51:361-70. 10.3109\/13693786.2012.738312","journal-title":"Med Mycol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01998-13","article-title":"Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain","volume":"51","author":"Bassetti M","year":"2013","unstructured":"Bassetti M, Merelli M, Righi E, et al.. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol. 2013, 51:4167-72. 10.1128\/JCM.01998-13","journal-title":"J Clin Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006","volume":"17","author":"Park BJ","year":"2011","unstructured":"Park BJ, Pappas PG, Wannemuehler KA, et al.. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis. 2011, 17:1855-64. 10.3201\/eid1710.110087","journal-title":"Emerg Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.22037%2Faaem.v10i1.1608","article-title":"Comparing the Characteristics of Mucormycosis Between Cases with and without COVID-19; a Cross-sectional Study","volume":"10","author":"Sistanizad M","year":"2022","unstructured":"Sistanizad M, Aghajani MH, Haghighi M, et al.. Comparing the Characteristics of Mucormycosis Between Cases with and without COVID-19; a Cross-sectional Study. Arch Acad Emerg Med. 2022, 10:10.22037%2Faaem.v10i1.1608","journal-title":"Arch Acad Emerg Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander BD","year":"2013","unstructured":"Alexander BD, Johnson MD, Pfeiffer CD, et al.. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013, 56:1724-32. 10.1093\/cid\/cit136","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1482","article-title":"Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus","volume":"41","author":"White TC","year":"1997","unstructured":"White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1997, 41:1482-7. 10.1128\/AAC.41.7.1482","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis Pneumonia","volume":"63","author":"Viriyakosol S","year":"2019","unstructured":"Viriyakosol S, Kapoor M, Okamoto S, et al.. APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis Pneumonia. Antimicrob Agents Chemother. 2019, 63:10.1128%2FAAC.01715-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00425-18","article-title":"Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin-and multidrug-resistant Candida isolates in a mouse model of invasive Candidiasis","volume":"62","author":"Zhao Y","year":"2018","unstructured":"Zhao Y, Lee MH, Paderu P, et al.. Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin-and multidrug-resistant Candida isolates in a mouse model of invasive Candidiasis. Antimicrob Agents Chemother. 2018, 62:10.1128\/AAC.00425-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01028-22","article-title":"Activities of Manogepix and Comparators against 1,435 recent fungal isolates collected during an international surveillance program (2020)","volume":"66","author":"Pfaller MA","year":"2022","unstructured":"Pfaller MA, Huband MD, Rhomberg PR, Bien PA, Castanheira M. Activities of Manogepix and Comparators against 1,435 recent fungal isolates collected during an international surveillance program (2020). Antimicrob Agents Chemother. 2022, 66:e0102822. 10.1128\/aac.01028-22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.00570-11","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods","volume":"55","author":"Pfaller MA","year":"2011","unstructured":"Pfaller MA, Duncanson F, Messer SA, et al.. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2011, 55:10.1128%2FAAC.00570-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.04.012","article-title":"Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)","volume":"26","author":"Pfaller MA","year":"2021","unstructured":"Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019). J Glob Antimicrob Resist. 2021, 26:117-27. 10.1016\/j.jgar.2021.04.012","journal-title":"J Glob Antimicrob Resist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz022","article-title":"In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez O","year":"2019","unstructured":"Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019, 74:1295-9. 10.1093\/jac\/dkz022","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.05414-11","article-title":"Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods","volume":"56","author":"Castanheira M","year":"2012","unstructured":"Castanheira M, Duncanson FP, Diekema DJ, et al.. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012, 56:10.1128%2FAAC.05414-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr342","article-title":"Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods","volume":"66","author":"Pfaller MA","year":"2011","unstructured":"Pfaller MA, Watanabe N, Castanheira M, Messer SA, Jones RN. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. J Antimicrob Chemother. 2011, 66:2581-4. 10.1093\/jac\/dkr342","journal-title":"J Antimicrob Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00840-19","article-title":"In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017","volume":"63","author":"Pfaller MA","year":"2019","unstructured":"Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017. Antimicrob Agents Chemother. 2019, 63:10.1128\/AAC.00840-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart SR","year":"2017","unstructured":"Lockhart SR, Etienne KA, Vallabhaneni S, et al.. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017, 64:134-40. 10.1093\/cid\/ciw691","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01717-21","article-title":"In vitro antifungal activity of Manogepix and other antifungal agents against South African Candida auris isolates from bloodstream infections","volume":"10","author":"Maphanga TG","year":"2022","unstructured":"Maphanga TG, Mpembe RS, Naicker SD, Govender NP. In vitro antifungal activity of Manogepix and other antifungal agents against South African Candida auris isolates from bloodstream infections. Microbiol Spectr. 2022, 10:e0171721. 10.1128\/spectrum.01717-21","journal-title":"Microbiol Spectr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01124-20","article-title":"In vitro activity of Manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak","volume":"64","author":"Zhu Y","year":"2020","unstructured":"Zhu Y, Kilburn S, Kapoor M, Chaturvedi S, Shaw KJ, Chaturvedi V. In vitro activity of Manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak. Antimicrob Agents Chemother. 2020, 64:10.1128\/AAC.01124-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of apx001a\/apx001 and other Gwt1 inhibitors against Cryptococcus","volume":"62","author":"Shaw KJ","year":"2018","unstructured":"Shaw KJ, Schell WA, Covel J, et al.. In vitro and in vivo evaluation of apx001a\/apx001 and other Gwt1 inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018, 62:10.1128\/AAC.00523-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/traa163","article-title":"Development of the global Mycetoma working group","volume":"115","author":"Traxler RM","year":"2021","unstructured":"Traxler RM, Beer KD, Blaney DD, et al.. Development of the global Mycetoma working group. Trans R Soc Trop Med Hyg. 2021, 115:437-40. 10.1093\/trstmh\/traa163","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(15)00359-x","article-title":"Mycetoma: a unique neglected tropical disease","author":"Zijlstra EE","year":"2016","unstructured":"Zijlstra EE, van de Sande WWJ, Welsh O, et al.. Mycetoma: a unique neglected tropical disease. Lancet Infectious Diseases. 2016, 10.1016\/s1473-3099(15)00359-x","journal-title":"Lancet Infectious Diseases"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00449-20","article-title":"Threats posed by the fungal kingdom to humans, wildlife, and agriculture","volume":"11","author":"Fisher MC","year":"2020","unstructured":"Fisher MC, Gurr SJ, Cuomo CA, et al.. Threats posed by the fungal kingdom to humans, wildlife, and agriculture. mBio. 2020, 11:10.1128\/mBio.00449-20","journal-title":"mBio"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002667","article-title":"The mycetoma knowledge gap: identification of research priorities","volume":"8","author":"van de Sande WW","year":"2014","unstructured":"van de Sande WW, Maghoub el S, Fahal AH, Goodfellow M, Welsh O, Zijlstra E. The mycetoma knowledge gap: identification of research priorities. PLoS Negl Trop Dis. 2014, 8:e2667. 10.1371\/journal.pntd.0002667","journal-title":"PLoS Negl Trop Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad118","article-title":"The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo","volume":"61","author":"Konings M","year":"2023","unstructured":"Konings M, Eadie K, Strepis N, Nyuykonge B, Fahal AH, Verbon A, van de Sande WW. The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo. Med Mycol. 2023, 61:10.1093\/mmy\/myad118","journal-title":"Med Mycol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myw060","article-title":"The anti-Aspergillus drug pipeline: Is the glass half full or empty?","volume":"55","author":"Osherov N","year":"2017","unstructured":"Osherov N, Kontoyiannis DP. The anti-Aspergillus drug pipeline: Is the glass half full or empty?. Med Mycol. 2017, 55:118-24. 10.1093\/mmy\/myw060","journal-title":"Med Mycol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of Fosmanogepix (apx001) in the treatment of candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene R","year":"2021","unstructured":"Petraitiene R, Petraitis V, Maung BB, et al.. Efficacy and pharmacokinetics of Fosmanogepix (apx001) in the treatment of candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits. Antimicrob Agents Chemother. 2021, 65:10.1128\/AAC.01795-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093%2Fofid%2Fofx163.1209","article-title":"Absorption, distribution, and excretion of 14C-APX001 after single-dose administration to rats and monkeys","volume":"4","author":"Mansbach R","year":"2017","unstructured":"Mansbach R, Shaw KJ, Hodges MR, et al.. Absorption, distribution, and excretion of 14C-APX001 after single-dose administration to rats and monkeys. Open Forum Infect Dis. 2017, 4:10.1093%2Fofid%2Fofx163.1209","journal-title":"Open Forum Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01225-18","article-title":"APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method","volume":"62","author":"Arendrup MC","year":"2018","unstructured":"Arendrup MC, Chowdhary A, Astvad KM, J\u00f8rgensen KM. APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother. 2018, 62:10.1128\/AAC.01225-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji S","year":"2020","unstructured":"Alkhazraji S, Gebremariam T, Alqarihi A, et al.. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother. 2020, 64:10.1128%2FAAC.01735-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.00178-20","article-title":"Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to rhizopus arrhizus","volume":"64","author":"Gebremariam T","year":"2020","unstructured":"Gebremariam T, Alkhazraji S, Alqarihi A, et al.. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to rhizopus arrhizus. Antimicrob Agents Chemother. 2020, 64:10.1128%2FAAC.00178-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.01120-19","article-title":"Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of candida auris invasive candidiasis","volume":"63","author":"Wiederhold NP","year":"2019","unstructured":"Wiederhold NP, Najvar LK, Shaw KJ, et al.. Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of candida auris invasive candidiasis. Antimicrob Agents Chemother. 2019, 63:10.1128%2FAAC.01120-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1390","article-title":"Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability","volume":"4","author":"Hodges MR","year":"2017","unstructured":"Hodges MR, Ople E, Shaw KJ, et al.. Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability. Open Forum Infect Dis. 2017, 4:10.1093\/ofid\/ofx163.1390","journal-title":"Open Forum Infect Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1370","article-title":"First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects","volume":"4","author":"Hodges MR","year":"2017","unstructured":"Hodges MR, Ople E, Shaw KJ, et al.. First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects. Open Forum Infect Dis. 2017, 4:10.1093\/ofid\/ofx163.1370","journal-title":"Open Forum Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12755","article-title":"Aspergillus calidoustus case series and review of the literature","volume":"19","author":"Seroy J","year":"2017","unstructured":"Seroy J, Antiporta P, Grim SA, Proia LA, Singh K, Clark NM. Aspergillus calidoustus case series and review of the literature. Transpl Infect Dis. 2017, 19:10.1111\/tid.12755","journal-title":"Transpl Infect Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1128%2Faac.02206-21","article-title":"Successful treatment of disseminated disease due to highly resistant Aspergillus calidoustus with a novel antifungal therapy","volume":"66","author":"Camargo JF","year":"2022","unstructured":"Camargo JF, Jabr R, Anderson AD, et al.. Successful treatment of disseminated disease due to highly resistant Aspergillus calidoustus with a novel antifungal therapy. Antimicrob Agents Chemother. 2022, 66:10.1128%2Faac.02206-21","journal-title":"Antimicrob Agents Chemother"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1055\/a-1535-2981","article-title":"Disseminated cerebral fusariosis in a liver-transplant patient: A case report and review of the literature","volume":"60","author":"Stropnicky P","year":"2022","unstructured":"Stropnicky P, He\u00df K, Becker T, Braun F. Disseminated cerebral fusariosis in a liver-transplant patient: A case report and review of the literature. Z Gastroenterol. 2022, 60:1231-4. 10.1055\/a-1535-2981","journal-title":"Z Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1128%2FCMR.00014-07","article-title":"Fusarium infections in immunocompromised patients","author":"Nucci M","year":"2007","unstructured":"Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Vol. 20, Clinical Microbiology Reviews. 2007, 10.1128%2FCMR.00014-07","journal-title":"Vol. 20, Clinical Microbiology Reviews"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20 Suppl 3","author":"Tortorano AM","year":"2014","unstructured":"Tortorano AM, Richardson M, Roilides E, et al.. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014, 20 Suppl 3:27-46. 10.1111\/1469-0691.12465","journal-title":"Clin Microbiol Infect"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1071428","article-title":"Fusarium meningoencephalitis in a child with acute leukemia","volume":"22","author":"Agamanolis DP","year":"1991","unstructured":"Agamanolis DP, Kalwinsky DK, Krill CE Jr, Dasu S, Halasa B, Galloway PG. Fusarium meningoencephalitis in a child with acute leukemia. Neuropediatrics. 1991, 22:110-2. 10.1055\/s-2008-1071428","journal-title":"Neuropediatrics"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad309","article-title":"Fosmanogepix therapy of disseminated Fusarium infection","volume":"77","author":"Winston DJ","year":"2023","unstructured":"Winston DJ, Young PA, Schlamm HT, Schiller GJ. Fosmanogepix therapy of disseminated Fusarium infection. Clin Infect Dis. 2023, 77:848-50. 10.1093\/cid\/ciad309","journal-title":"Clin Infect Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad285","article-title":"Successful use of Fosmanogepix for treatment of rare highly resistant cutaneous Fusariosis in a pediatric patient with STAT3 hyper-immunoglobulin E syndrome and end-stage kidney disease","volume":"10","author":"Goggin KP","year":"2023","unstructured":"Goggin KP, Londeree J, Freeman AF, Garro R, George RP. Successful use of Fosmanogepix for treatment of rare highly resistant cutaneous Fusariosis in a pediatric patient with STAT3 hyper-immunoglobulin E syndrome and end-stage kidney disease. Open Forum Infect Dis. 2023, 10:ofad285. 10.1093\/ofid\/ofad285","journal-title":"Open Forum Infect Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad269","article-title":"Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia","volume":"78","author":"Cornely OA","year":"2023","unstructured":"Cornely OA, Ostermann H, Koehler P, et al.. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. J Antimicrob Chemother. 2023, 78:2645-52. 10.1093\/jac\/dkad269","journal-title":"J Antimicrob Chemother"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial","volume":"78","author":"Pappas PG","year":"2023","unstructured":"Pappas PG, Vazquez JA, Oren I, et al.. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. J Antimicrob Chemother. 2023, 78:2471-80. 10.1093\/jac\/dkad256","journal-title":"J Antimicrob Chemother"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with Candidemia caused by Candida auris: results from a phase 2 trial","volume":"67","author":"Vazquez JA","year":"2023","unstructured":"Vazquez JA, Pappas PG, Boffard K, et al.. Clinical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with Candidemia caused by Candida auris: results from a phase 2 trial. Antimicrob Agents Chemother. 2023, 67:e0141922. 10.1128\/aac.01419-22","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222922-fosmanogepix-the-novel-anti-fungal-agents-comprehensive-review-of-in-vitro-in-vivo-and-current-insights-from-advancing-clinical-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T14:24:18Z","timestamp":1714314258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222922-fosmanogepix-the-novel-anti-fungal-agents-comprehensive-review-of-in-vitro-in-vivo-and-current-insights-from-advancing-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,28]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.59210","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,28]]}}}